Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Aiming T-cell engagers at autoimmune diseases continues to be a red-hot dealmaking target.
James Waldron
Jun 23, 2025 6:29am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
German cancer antibody biotech eyes SPAC as route to Nasdaq
Apr 23, 2025 6:09am
ADCs to cell therapy: How AZ aims to 'redefine' oncology
Apr 9, 2025 11:44am
BioAtla lays off 30% of staff, hunts for ADC partners
Mar 28, 2025 6:30am
